Multi-Omics Characterization of Improved Cognitive Functions in Parkinson’s Disease Patients After The Combined Metabolic Activator Treatment

Objective

To investigate whether supplementation of combined metabolic activators (CMA) consisting of NR, L-carnitine tartrate, serine, and N-acetyl-L-cysteine (NAC), could be used to treat Parkinson’s disease (PD) patients.

Study Design

Randomized, double-blind, placebo-controlled, phase II study in 48 PD patients

Dose

2000 mg

One dose of 12.35g L-serine, 1g NR, 2.55g N-acetyl-L-cysteine, and 3.73g L-carnitine tartrate for the first 28 days and two doses for the next 56 days.

Duration

12 weeks

Key Outcomes

  • CMA supplementation did not improve motor function in PD patients.

  • CMA significantly improved cognitive function, particularly in patients with low baseline MoCA scores, indicative of worsened cognitive function. However, the variability in baseline MoCA scores likely influenced the observed outcomes.

Clinical, Neurological HealthANAD Staff